Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Xenazine

AstraZeneca AZ

Setback for AZ as tralokinumab flunks asthma trial

Puts more pressure on AZ’s benralizumab to reach its potential

- PMLiVE

AZ gets early FDA green light for Imbruvica challenger

Sets up a marketing battle with Johnson/AbbVie

FDA approves new robotic surgery device

Senhance System backed for colorectal and gynaecological operations

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

- PMLiVE

Lundbeck and Otsuka start phase III for Rexulti in bipolar

Drug is also in phase II trial to treat PTSD patients

Roche - Basel

Roche and J&J picked for ‘revolutionary’ digital health pilot

Firms will line up alongside Apple, Fitbit, Samsung and Verily in FDA pre-certification programme

Roche and J&J picked for ‘revolutionary’ digital health pilot

Firms will line up alongside Apple, Fitbit, Samsung and Verily in FDA pre-certification programme

- PMLiVE

FDA grants orphan drug status to UniQure’s Huntington’s Disease treatment

Becomes first investigational gene therapy to receive ODD for the disease

- PMLiVE

Teva faces early rival to longer-acting Copaxone in US

US regulator approves Mylan’s MS drug

- PMLiVE

J&J seeks US OK to add CV claim to Invokana label

If approved the treatment could better compete with rivals Jardiance and Victoza

UK flag

Universal flu vaccine heads for UK trials

New vaccine targets core proteins of the virus

- PMLiVE

FDA wants more data on J&J’s arthritis drug Plivensia

Requests further evidence on the drug’s safety profile after patient deaths link

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links